PURPOSE: To report the long-term outcomes of @entity291 ureter grafts as novel conduits for haemodialysis @entity292 . MATERIALS AND METHODS: Thirty-five @entity1 underwent placement of a total of 40 SynerGraft 100 (SG100; CryoLife Europa(  ), Guildford, UK) @entity291 ureter grafts between April 2002 and February 2009. Prospective data were collected on all @entity1 , including active surveillance with blood flow studies and 6-monthly duplex ultrasound studies. Main outcome measures were primary and secondary patency rates. RESULTS: Mean follow-up time was 97  weeks (range 4-270). Thirteen @entity1 died from unrelated causes during the study period; 12 of these @entity1 had a functioning graft at the time of @entity204 . Five @entity1 underwent transplantation, and all had a functioning graft at transplantation. Twelve @entity1 had a functioning graft at the end of the study period. One hundred and ten stenoses were detected, and 97 venoplasty procedures were performed. Of the stenoses, 41.8% were located at the venous anastomosis, 12.7% within the graft, 17.3% in the outflow veins, and 28.1% in central veins. No arterial stenoses were detected. Primary patency rates were 53% at 6  months and 14% at 1  year. Secondary patency rates were 81% at 6  months, 75% at 1  year, and 56% at 2  years. CONCLUSIONS: Active surveillance and intervention was able to achieve satisfactory long-term secondary patency for these novel conduits compared with those made of PTFE seen in other studies [1].

Results of a seven-year, single-centre experience of the long-term outcomes of XXXX ureter grafts used as novel conduits for haemodialysis @entity292 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity292 :: ('MESH:D005402', 'Disease') :: ['fistulas'] @entity291 :: ('9913', 'Species') :: ['bovine'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity291 :: (9913,Species) :: ['bovine']
